Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H
复制标题
DOI：
10.1016/j.jcv.2005.10.009
复制
发表时间：
2006-04-01
影响因子：
8.8
通讯作者：
Lampertico, Pietro
中科院分区：
文献类型：
--
作者：
Cortelezzi, Agostino;Vigano, Mauro;Lampertico, Pietro
我们描述了一名 49 岁男性隐匿性乙型肝炎病毒感染严重再激活的病例，该男性因患有 Binet A 期 B 细胞慢性淋巴细胞白血病 (B-CLL) 而接受高剂量苯丁酸氮芥治疗。该患者最初接受拉米夫定治疗，随后接受拉米夫定和阿德福韦酯联合治疗，以控制病毒复制，并允许使用阿仑单抗 (Campath-1H) 进行长期抗癌化疗，阿仑单抗用于挽救 B-CLL 复发。在 20 个月的抗 HBV 治疗期间，ALT 和 HBV-DNA 水平逐渐下降，并且通过长期阿仑单抗给药成功控制了 B-CLL。 (C) 2005 Elsevier B.V. 保留所有权利。
We describe a case of severe reactivation of occult hepatitis B virus infection in a 49-year-old man, who was treated with high doses of chlorambucil for a Binet stage A B-cell chronic lymphocytic leukemia (B-CLL). The patient was initially treated with lamivudine and subsequently with lamivudine and adefovir dipivoxil combination therapy to control viral replication and allow for long-term anti-cancer chemotherapy with alemtuzumab (Campath-1H), which was introduced to rescue for a B-CLL relapse. During 20 months of anti-HBV therapy, ALT and HBV-DNA levels progressively declined and B-CLL was successfully kept under control by long-term alemtuzumab administration. (C) 2005 Elsevier B.V. All rights reserved.